Clinical trials
Neuroendocrine Tumors clinical trials
Below are recruiting neuroendocrine tumors clinical trials, each written for real people, not researchers. We’re tracking 173 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06427798RecruitingPhase 1/Phase 2
Radioactive drug for previously treated gut or adrenal tumors
This trial tests a new radioactive drug, [212Pb]VMT-alpha-NET, that targets a receptor found on some tumor cells. It is for people with certain gut or adrenal gland tumors that have already been treated with a similar therapy but are still growing.
Bethesda, MarylandAges 18–120 - NCT01174121RecruitingPhase 2
Immunotherapy made from your tumor-fighting immune cells
This trial tests a treatment made from your own immune cells (called tumor-infiltrating lymphocytes, or TILs) for certain metastatic cancers. It’s designed for people whose cancer has not responded to standard treatments and who can safely provide a small tumor sample for cell-making.
Bethesda, MarylandAges 18–72 - NCT03206060RecruitingPhase 2
Lu-177 DOTATATE for hard-to-remove pheochromocytoma or paraganglioma
This trial studies Lu-177 DOTATATE (Lutathera), a targeted radiation medicine, for tumors that cannot be safely removed with surgery. It aims to shrink or control pheochromocytoma/paraganglioma that is showing recent growth and has a specific target signal on a special PET scan.
Bethesda, MarylandAges 18–100 - NCT04888481RecruitingPhase 2
Scan with a marker to find certain slow-growing tumors
This study tests an imaging scan using a special tracer (68Ga-HA-DOTATATE) to look for tumors that have somatostatin receptors. It may help doctors better locate suspected tumor sites so treatment planning can be more accurate.
Edmonton, AlbertaAges Any age - NCT05069220RecruitingEarly Phase 1
PET/CT scan to study neural crest tumors
This early-phase trial uses a special PET/CT scan to help evaluate neural crest tumors, which include conditions like neuroblastoma. It may help doctors understand how well the scan shows tumor activity to guide diagnosis and treatment planning.
Beijing, DongchengAges 1–80 - NCT06242119Recruiting
Testing a new PET scanner prototype
This study is testing a new type of PET scanner (called J-PET) to see if it works as well as current PET/CT machines. If you are already scheduled for a whole-body PET/CT scan, participating would mean your scan is done with this experimental scanner instead.
KrakowAges 18 years+ - NCT06276309Recruiting
Protein study of cervical neuroendocrine tumors
This study looks at the proteins in cervical neuroendocrine tumors to understand how they behave and how they affect long-term outcomes. It aims to find new markers that could help predict prognosis and guide treatment.
Fuzhou, FujianAges Any age - NCT06943521RecruitingPhase 1/Phase 2
Study of MT-4561 for advanced solid tumors
This trial tests a new drug called MT-4561 in people with advanced solid tumors that have not responded to prior treatments. It aims to see if the drug can help shrink tumors or slow their growth.
Los Angeles, CaliforniaAges 18 years+ - NCT05847855Recruiting
Blood test to help detect certain early pancreatic tumors
This study looks at a special analysis of your blood (called cfDNA fragmentomics) to help find and tell apart certain early pancreatic tumors. If you’re having surgery for one of the listed solid pancreatic tumors, this trial may use your blood samples to improve diagnosis.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT04706910RecruitingPhase 3
PET scan study to optimize imaging in several diseases
This trial improves a special PET scan (a type of brain/body imaging) using 18F-DOPA, to better show how certain conditions behave in the body. If you or your child may have one of the listed conditions, the study may help your doctors get clearer scan results.
Edmonton, AlbertaAges Any age - NCT04837885RecruitingPhase 2
Liver-targeted radioactive drug for GI or pancreas NET liver spread
This study tests a way to deliver a radioactive “somatostatin-type” medicine directly into the liver artery to treat liver-dominant spread of neuroendocrine tumors (NETs). It may help shrink or control liver metastases after standard treatment has not worked enough.
BordeauxAges 18 years+ - NCT05053854RecruitingPhase 1
Testing a PARP drug plus targeted radiation for bowel or pancreas tumors
This Phase 1 study tests how safe and effective it is to combine a PARP inhibitor (a targeted cancer medicine) with PRRT, a treatment that delivers radiation directly to certain tumor cells. It is for people with grade 2 neuroendocrine tumors from the pancreas or intestines, especially when scans suggest the tumor will take up the targeted radiation.
Melbourne, VictoriaAges 18 years+ - NCT05178693RecruitingPhase 1
Testing Lutathera with ASTX727 for neuroendocrine tumors
This Phase 1 study tests how well Lutathera combined with ASTX727 can treat neuroendocrine tumors. It looks mainly at whether the combination can be given safely and effectively for people whose tumors have grown or not tolerated standard first treatment.
London, London, City ofAges 18–99 - NCT05556473RecruitingPhase 1
Tryptophan PET/CT scan study for different tumors
This early-phase study tests a special PET/CT scan using labeled tryptophan to help doctors see how different tumors behave. The goal is to learn whether this scan can better identify and measure cancers in the brain or elsewhere.
Detroit, MichiganAges 18 years+ - NCT06345079RecruitingPhase 2
Stopping Somatostatin Analogues After PRRT for NETs
This trial tests whether it's safe to stop somatostatin analogues (SSAs) after PRRT (a type of radiation therapy for neuroendocrine tumors). It is for people with midgut, hindgut, or pancreatic NETs that have not responded to SSAs and now need PRRT.
Sydney, New South WalesAges 18 years+ - NCT07132645RecruitingEarly Phase 1
New scan for high-grade neuroendocrine cancer
This trial tests a new type of PET/CT scan called [68Ga]Ga-FAPI-04 to see if it can better detect high-grade neuroendocrine tumors. It is for patients whose standard scans show low uptake or who have aggressive tumor features.
Ann Arbor, MichiganAges 18 years+ - NCT06788938RecruitingPhase 2
Tarlatamab for advanced DLL3-positive tumors
This trial tests a drug called tarlatamab for people with advanced cancers that have a specific protein called DLL3. It aims to see if this treatment can help when other treatments have stopped working.
Davis, CaliforniaAges 18 years+ - NCT05500391RecruitingPhase 2
Testing whether remote nurse monitoring works like in-person checks
This Phase 2 study compares two ways of checking your cancer follow-up: a doctor or nurse visits in person versus remote monitoring by phone and imaging. The goal is to see whether remote monitoring can safely replace or match in-person care for certain low-risk cancers and after surgery.
AmiensAges 18 years+ - NCT06141369Recruiting
Personalized mRNA vaccine for advanced endocrine tumors
This trial tests a personalized mRNA vaccine made from your tumor's genetic information. It is for people with advanced endocrine tumors who have no standard treatment options left, and aims to help the immune system fight the cancer.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT04104529Recruiting
Registry study for adults getting metabolic radiotherapy
This trial collects health and lab information from adults treated with metabolic radiotherapy in the nuclear medicine department. It may help doctors better understand how these treatments work for thyroid cancer, neuroendocrine tumors, or prostate cancer.
Bordeaux, AquitaineAges 18 years+ - NCT04893785RecruitingPhase 2
Cabozantinib plus temozolomide for advanced neuroendocrine lung tumors
This Phase 2 study tests whether combining cabozantinib with temozolomide can control advanced lung or gastrointestinal neuroendocrine tumors that have grown after prior treatments. It also closely monitors safety, including blood counts, organ function, and other side effects.
Naples, CampaniaAges 18 years+ - NCT06876532Recruiting
Inflammation score and Lu-177 treatment for midgut NET
This study looks at whether a simple blood test (inflammation score) can predict how well the drug Lu-177 oxodotreotide (Lutathera) will work for people with midgut neuroendocrine tumors that have grown or spread. It may help doctors understand who benefits most from this treatment.
AngersAges 18 years+ - NCT05243082Recruiting
Ultrasound-guided heating treatment for pancreatic neuroendocrine tumors
This trial tests a procedure that uses an endoscope and ultrasound to heat (radiofrequency ablate) pancreatic neuroendocrine tumors. It may help shrink tumors while aiming to be a less invasive option.
OsloAges 18 years+ - NCT06121622Recruiting
Personalized 3D models for pancreatic neuroendocrine tumors
This study is testing a new way to make 3D models in the lab that look like your specific tumor. The goal is to better understand pancreatic neuroendocrine tumors and find personalized treatments.
Milan, MIAges 18 years+
Hear when a new Neuroendocrine Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for neuroendocrine tumors?
- Yes. Clin2 currently lists 173 recruiting neuroendocrine tumors studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a neuroendocrine tumors trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a neuroendocrine tumors trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.